Ocular Therapeutix, Inc. (NASDAQ:OCUL) Receives $16.25 Consensus Target Price from Analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have covered the stock in the last year is $16.25.

Several equities research analysts have issued reports on the stock. Needham & Company LLC lowered their price target on shares of Ocular Therapeutix from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Tuesday, May 6th. William Blair started coverage on shares of Ocular Therapeutix in a research report on Tuesday, April 8th. They set an "outperform" rating on the stock. Royal Bank Of Canada assumed coverage on shares of Ocular Therapeutix in a research report on Tuesday, March 18th. They issued an "outperform" rating and a $17.00 price target for the company. HC Wainwright restated a "buy" rating and set a $15.00 price target on shares of Ocular Therapeutix in a research note on Thursday, May 29th. Finally, JMP Securities set a $19.00 price objective on Ocular Therapeutix in a report on Tuesday, March 4th.

Insider Buying and Selling at Ocular Therapeutix

In other news, insider Pravin Dugel sold 21,219 shares of Ocular Therapeutix stock in a transaction that occurred on Friday, May 23rd. The shares were sold at an average price of $7.18, for a total value of $152,352.42. Following the completion of the transaction, the insider now owns 3,499,099 shares in the company, valued at approximately $25,123,530.82. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Richard L. Md Lindstrom purchased 10,000 shares of the firm's stock in a transaction that occurred on Thursday, May 8th. The shares were acquired at an average price of $6.96 per share, for a total transaction of $69,600.00. Following the completion of the transaction, the director now owns 172,704 shares in the company, valued at $1,202,019.84. The trade was a 6.15% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold a total of 29,079 shares of company stock worth $208,739 over the last ninety days. Corporate insiders own 2.30% of the company's stock.

Institutional Trading of Ocular Therapeutix

Several large investors have recently made changes to their positions in OCUL. GF Fund Management CO. LTD. bought a new position in shares of Ocular Therapeutix in the fourth quarter valued at about $28,000. Atlas Capital Advisors Inc. bought a new position in shares of Ocular Therapeutix in the fourth quarter worth about $43,000. Brooklyn Investment Group raised its stake in shares of Ocular Therapeutix by 151.5% in the first quarter. Brooklyn Investment Group now owns 5,238 shares of the biopharmaceutical company's stock worth $38,000 after acquiring an additional 3,155 shares during the last quarter. AlphaQuest LLC acquired a new position in shares of Ocular Therapeutix during the fourth quarter worth approximately $53,000. Finally, GAMMA Investing LLC grew its stake in shares of Ocular Therapeutix by 6,760.0% during the first quarter. GAMMA Investing LLC now owns 8,232 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 8,112 shares during the last quarter. Institutional investors own 59.21% of the company's stock.

Ocular Therapeutix Stock Performance

Shares of OCUL stock traded up $0.03 during mid-day trading on Friday, reaching $8.33. The stock had a trading volume of 1,643,504 shares, compared to its average volume of 1,440,929. The firm's 50 day simple moving average is $7.82 and its 200 day simple moving average is $7.86. The company has a quick ratio of 10.14, a current ratio of 10.22 and a debt-to-equity ratio of 0.26. Ocular Therapeutix has a one year low of $5.79 and a one year high of $11.78. The firm has a market cap of $1.33 billion, a PE ratio of -7.24 and a beta of 1.42.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.